Outcome measures in MMN revisited: Further improvement needed

Journal of the Peripheral Nervous System

Volumn 20, Issue 3, 2015, Pages 306-318

  Pruppers, Mariëlle H J ^a   Draak, Thomas H P ^a   Vanhoutte, Els K ^a   Van Der Pol, W Ludo ^b   Gorson, Kenneth C ^c   Léger, Jean Marc ^d   Nobile Orazio, Eduardo ^e   Lewis, Richard A ^f   Van Den Berg, Leonard H ^b   Faber, Catharina G ^a   Merkies, Ingemar S J ^a,g  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e UNIVERSITY OF MILAN   (Italy)

^f CEDARS SINAI MEDICAL CENTER   (United States)

^g Department of Orthopaedic Surgery   (Netherlands)

Author keywords

MMN; outcome measure

Indexed keywords

IMMUNOGLOBULIN; IMMUNOLOGIC FACTOR;

ADULT; AGED; ARM MUSCLE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FUNCTIONAL STATUS ASSESSMENT; GENERAL CONDITION DETERIORATION; GRIP STRENGTH; HUMAN; LONGITUDINAL STUDY; MALE; MOTOR NEUROPATHY; NEUROLOGIC DISEASE ASSESSMENT; NEUROPATHY IMPAIRMENT SCALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASCH ANALYSIS; RASCH BUILT OVERALL DISABILITY SCALE; SELF EVALUATION; SHORT FORM 36; BIBLIOGRAPHIC DATABASE; DISABILITY; MIDDLE AGED; POLYNEUROPATHIES; RANDOMIZED CONTROLLED TRIAL; STATISTICS AND NUMERICAL DATA;

ADULT; AGED; DATABASES, BIBLIOGRAPHIC; DISABILITY EVALUATION; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); POLYNEUROPATHIES;

EID: 84942590946     PISSN: 10859489     EISSN: 15298027     Source Type: Journal    
DOI: 10.1111/jns.12124     Document Type: Article

References (59)

1. Aaronson NK, (1988). Quality of life: what is it? How should it be measured? Oncology 2: 69-76.
2. Akaza M, Kanouchi T, Inaba A, Numasawa Y, Irioka T, Mizusawa H, Yokota T, (2011). Motor nerve conduction study in cauda equina with high-voltage electrical stimulation in multifocal motor neuropathy and amyotrophic lateral sclerosis. Muscle Nerve 43: 274-282.
3. Andrich D, Sheridan B, Luo G, (2010). Rasch Models For Measurement: RUMM2030. Perth: RUMM Laboratory Pty Ltd.
4. Arunachalam R, Osei-Lah A, Mills KR, (2003). Transcutaneous cervical root stimulation in the diagnosis of multifocal motor neuropathy with conduction block. J Neurol Neurosurg Psychiatry 74: 1329-1331.
5. Attarian S, Azulay JP, Verschueren A, Pouget J, (2005). Magnetic stimulation using a triple-stimulation technique in patients with multifocal neuropathy without conduction block. Muscle Nerve 32: 710-714.
6. Azulay JP, Blin O, Pouget J, Boucraut J, Bille-Turc F, Carles G, Serratrice G, (1994). Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti-GM1 antibodies: a double-blind, placebo-controlled study. Neurology 44: 429-432.
7. Baumann A, Hess CW, Sturzenegger M, (2009). IVIg dose increase in multifocal motor neuropathy: a prospective six month follow-up. J Neurol 256: 608-614.
8. Beaton DE, Boers M, Wells GA, (2002). Many faces of the minimal clinically important difference (MCID): a literature review and directions for future research. Curr Opin Rheumatol 14: 109-114.
9. Braine ME, Woodall A, (2012). A comparison between intravenous and subcutaneous immunoglobulin. Br J Nurs 21 S21-22: S24-S27.
10. Cats EA, van der Pol WL, Piepers S, Notermans NC, van den Berg-Vos RM, van den Berg LH, (2008). New liquid intravenous immunoglobulin (10 % IVIg) for treatment of multifocal motor neuropathy: a prospective study of efficacy, safety and tolerability. J Neurol 255: 1598-1599.
11. Chaudhry V, Cornblath DR, (2010). An open-label trial of rituximab (Rituxan(R)) in multifocal motor neuropathy. J Peripher Nerv Syst 15: 196-201.
12. Comi G, Amadio S, Galardi G, Fazio R, Nemni R, (1994). Clinical and neurophysiological assessment of immunoglobulin therapy in five patients with multifocal motor neuropathy. J Neurol Neurosurg Psychiatry 57 (Suppl.): 35-37.
13. De Land PN, Chase WW, (1990). Entry I.J, types of data: nominal, ordinal, interval, and ratio scales. Optom Vis Sci 67: 155-156.
14. Delmont E, Azulay JP, Giorgi R, Attarian S, Verschueren A, Uzenot D, Pouget J, (2006). Multifocal motor neuropathy with and without conduction block: a single entity? Neurology 67: 592-596.
15. Draak TH, Vanhoutte EK, van Nes SI, Gorson KC, Van der Pol WL, Notermans NC, Nobile-Orazio E, Leger JM, Van den Bergh PY, Lauria G, Bril V, Katzberg H, Lunn MP, Pouget J, van der Kooi AJ, Hahn AF, Doorn PA, Cornblath DR, van den Berg LH, Faber CG, Merkies IS, PeriNom SSG, (2014). Changing outcome in inflammatory neuropathies: Rasch-comparative responsiveness. Neurology 83: 2124-2132.
16. Dyck PJ, Kratz KM, Lehman KA, Karnes JL, Melton LJ 3rd, O'Brien PC, Litchy WJ, Windebank AJ, Smith BE, Low PA, Service FJ, Rizza RA, Zimmerman BR, (1991). The Rochester Diabetic Neuropathy Study: design, criteria for types of neuropathy, selection bias, and reproducibility of neuropathic tests. Neurology 41: 799-807.
17. Eftimov F, Vermeulen M, de Haan RJ, van den Berg LH, van Schaik IN, (2009). Subcutaneous immunoglobulin therapy for multifocal motor neuropathy. J Peripher Nerv Syst 14: 93-100.
18. Federico P, Zochodne DW, Hahn AF, Brown WF, Feasby TE, (2000). Multifocal motor neuropathy improved by IVIg: randomized, double-blind, placebo-controlled study. Neurology 55: 1256-1262.
19. Fitzpatrick AM, Mann CA, Barry S, Brennan K, Overell JR, Willison HJ, (2011). An open label clinical trial of complement inhibition in multifocal motor neuropathy. J Peripher Nerv Syst 16: 84-91.
20. Ghosh A, Virgincar A, Kennett R, Busby M, Donaghy M, (2005). The effect of treatment upon temporal dispersion in IvIg responsive multifocal motor neuropathy. J Neurol Neurosurg Psychiatry 76: 1269-1272.
21. Gorson KC, Ropper AH, Weinberg DH, (1999). Upper limb predominant, multifocal chronic inflammatory demyelinating polyneuropathy. Muscle Nerve 22: 758-765.
22. Gorson KC, Natarajan N, Ropper AH, Weinstein R, (2007). Rituximab treatment in patients with IVIg-dependent immune polyneuropathy: a prospective pilot trial. Muscle Nerve 35: 66-69.
23. Hahn AF, Beydoun SR, Lawson V, Team IiMS OM, Empson VG, Leibl H, Ngo LY, Gelmont D, Koski CL, (2013). A controlled trial of intravenous immunoglobulin in multifocal motor neuropathy. J Peripher Nerv Syst 18: 321-330.
24. Harbo T, Andersen H, Hess A, Hansen K, Sindrup SH, Jakobsen J, (2009). Subcutaneous versus intravenous immunoglobulin in multifocal motor neuropathy: a randomized, single-blinded cross-over trial. Eur J Neurol 16: 631-638.
25. Harbo T, Andersen H, Jakobsen J, (2010). Long-term therapy with high doses of subcutaneous immunoglobulin in multifocal motor neuropathy. Neurology 75: 1377-1380.
26. Hoang-Xuan K, Leger JM, Ben Younes-Chennoufi A, Saidi H, Bouche P, Baumann N, Brunet P, (1993). Treatment of immune deficient neuropathies with intravenous polyvalent immunoglobulins. An open study of 16 cases. Rev Neurol (Paris) 149: 385-392.
27. Hobart J, Cano S, (2009). Improving the evaluation of therapeutic interventions in multiple sclerosis: the role of new psychometric methods. Health Technol Assess 13 iii, ix-x: 1-177.
28. Hughes RA, Donofrio P, Bril V, Dalakas MC, Deng C, Hanna K, Hartung HP, Latov N, Merkies IS, van Doorn PA, Group ICES (2008). Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol 7: 136-144.
29. Leger JM, Chassande B, Musset L, Meininger V, Bouche P, Baumann N, (2001). Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind, placebo-controlled study. Brain 124: 145-153.
30. Lehmann HC, Hoffmann FR, Fusshoeller A, Meyer zu Horste G, Hetzel R, Hartung HP, Schroeter M, Kieseier BC, (2008). The clinical value of therapeutic plasma exchange in multifocal motor neuropathy. J Neurol Sci 271: 34-39.
31. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D, (2009). The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 62: e1-e34.
32. Martina IS, van Doorn PA, Schmitz PI, Meulstee J, van der Meche FG, (1999). Chronic motor neuropathies: response to interferon-beta1a after failure of conventional therapies. J Neurol Neurosurg Psychiatry 66: 197-201.
33. Medical Research Council (1943). Aids to the Investigation of the Peripheral Nervous System. Her Majesty's Stationary Office, London.
34. Merkies IS, Lauria G, (2006). 131st ENMC International workshop: selection of outcome measures for peripheral neuropathy clinical trials 10-12 December 2004, Naarden, The Netherlands. Neuromuscul Disord 16: 149-156.
35. Merkies IS, Schmitz PI, Samijn JP, Meche FG, Toyka KV, van Doorn PA, (2000). Assessing grip strength in healthy individuals and patients with immune-mediated polyneuropathies. Muscle Nerve 23: 1393-1401.
36. Merkies IS, van Nes SI, Hanna K, Hughes RA, Deng C, (2010). Confirming the efficacy of intravenous immunoglobulin in CIDP through minimum clinically important differences: shifting from statistical significance to clinical relevance. J Neurol Neurosurg Psychiatry 81: 1194-1199.
37. Meucci N, Cappellari A, Barbieri S, Scarlato G, Nobile-Orazio E, (1997). Long term effect of intravenous immunoglobulins and oral cyclophosphamide in multifocal motor neuropathy. J Neurol Neurosurg Psychiatry 63: 765-769.
38. Misbah SA, Baumann A, Fazio R, Dacci P, Schmidt DS, Burton J, Sturzenegger M, (2011). A smooth transition protocol for patients with multifocal motor neuropathy going from intravenous to subcutaneous immunoglobulin therapy: an open-label proof-of-concept study. J Peripher Nerv Syst 16: 92-97.
39. Molinuevo JL, Cruz-Martinez A, Graus F, Serra J, Ribalta T, Valls-Sole J, (1999). Central motor conduction time in patients with multifocal motor conduction block. Muscle Nerve 22: 926-932.
40. van Nes SI, Faber CG, Merkies IS, (2008). Outcome measures in immune-mediated neuropathies: the need to standardize their use and to understand the clinimetric essentials. J Peripher Nerv Syst 13: 136-147.
41. Nobile-Orazio E, Cappellari A, Meucci N, Carpo M, Terenghi F, Bersano A, Priori A, Barbieri S, Scarlato G, (2002). Multifocal motor neuropathy: clinical and immunological features and response to IVIg in relation to the presence and degree of motor conduction block. J Neurol Neurosurg Psychiatry 72: 761-766.
42. Nodera H, Bostock H, Izumi Y, Nakamura K, Urushihara R, Sakamoto T, Murase N, Shimazu H, Kusunoki S, Kaji R, (2006). Activity-dependent conduction block in multifocal motor neuropathy: magnetic fatigue test. Neurology 67: 280-287.
43. Norman GR, Sloan JA, Wyrwich KW, (2003). Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care 41: 582-592.
44. Pazzaglia C, Briani C, Nobile-Orazio E, Caliandro P, Granata G, Tonali PA, Padua L, (2011). Occurrence and characterization of pain in immune-mediated neuropathies: a multicentre prospective study. Eur J Neurol 18: 177-183.
45. Piepers S, Van den Berg-Vos R, Van der Pol WL, Franssen H, Wokke J, Van den Berg L, (2007). Mycophenolate mofetil as adjunctive therapy for MMN patients: a randomized, controlled trial. Brain 130: 2004-2010.
46. van Schaik IN, van den Berg LH, de Haan R, Vermeulen M, (2005). Intravenous immunoglobulin for multifocal motor neuropathy. Cochrane Database Syst Rev 2: CD004429.
47. Sloan J, Symonds T, Vargas-Chanes D, Fridley B, (2003). Practical guidelines for assessing the clinical significance of health-related quality of life changes within clinical trials. Drug Inf J 37: 23-31.
48. Stevens SS, (1946). On the theory of scales of measurement. Science 103: 677-680.
49. Strigl-Pill N, Konig A, Schroder M, Beranek H, Schoser BG, Spaeth M, Pongratz D, Muller-Felber W, (2006). Prediction of response to IVIg treatment in patients with lower motor neurone disorders. Eur J Neurol 13: 135-140.
50. Stucki G, Daltroy L, Katz JN, Johannesson M, Liang MH, (1996). Interpretation of change scores in ordinal clinical scales and health status measures: the whole may not equal the sum of the parts. J Clin Epidemiol 49: 711-717.
51. van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J, (1988). Interobserver agreement for the assessment of handicap in stroke patients. Stroke 19: 604-607.
52. Van Asseldonk JT, Franssen H, Van den Berg-Vos RM, Wokke JH, Van den Berg LH, (2005). Multifocal motor neuropathy. Lancet Neurol 4: 309-319.
53. Van den Berg LH, Kerkhoff H, Oey PL, Franssen H, Mollee I, Vermeulen M, Jennekens FG, Wokke JH, (1995). Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry 59: 248-252.
54. Van den Berg LH, Franssen H, Wokke JH, (1998). The long-term effect of intravenous immunoglobulin treatment in multifocal motor neuropathy. Brain 121 (Pt 3): 421-428.
55. Van den Berg-Vos RM, Van den Berg LH, Franssen H, Van Doorn PA, Merkies IS, Wokke JH, (2000). Treatment of multifocal motor neuropathy with interferon-beta1A. Neurology 54: 1518-1521.
56. Vanhoutte EK, Faber CG, Merkies IS, on behalf of the PeriNomS Study group (2013). 196th ENMC international workshop: outcome measures in inflammatory peripheral neuropathies 8-10 February 2013, Naarden, The Netherlands. Neuromuscul Disord 23: 924-933.
57. ©). J Peripher Nerv Syst 20: 296-305.
58. Vlam L, Cats EA, Willemse E, Franssen H, Medic J, Piepers S, Veldink JH, van den Berg LH, van der Pol WL, (2014). Pharmacokinetics of intravenous immunoglobulin in multifocal motor neuropathy. J Neurol Neurosurg Psychiatry 85: 1145-1148.
59. World Health Organization (2001). ICF: International Classification of Functioning, Disability and Health. World Health Organization, Geneva.